From 4 to 8 March, the Agency is operating remotely.

EMA_New office

From 4 to 8 March, the Agency is operating remotely.

On Friday 01 March EMA has closed its London premises and has relocated to Amsterdam, the Netherlands.

From 4 March 2019, the official address of the Agency is that of its permanent building in Amsterdam Zuidas:

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

However, EMA will not physically occupy its permanent building until the latter part of 2019.

From 4 to 8 March, the Agency is operating remotely. From 11 to 15 March, EMA staff will gradually move into a temporary building in Amsterdam, called the Spark building.

As of 11 March 2019, all EMA face-to-face meetings will take place at the Spark building until EMA moves into its permanent building. The address below should be used for attending EMA meetings:

European Medicines Agency
Orlyplein 24
1043 DP Amsterdam
The Netherlands

EMA has published an Orientation Guide for Industry <https://www.ema.europa.eu/en/documents/other/orientation-guide-industry-spark-building_en.pdf> on the Spark Building, which includes detailed on how to get to the building, the facilities, and the arrangements that will be in place for pharmaceutical companies attending scientific meetings to ensure smooth operation and continuity.

The page www.ema.europa.eu/how-to-find-us  provides up-to-date address information, include information on the address for regular postal deliveries and consignments that require signature.

The main telephone number will be +31 (0)88 781 6000 and the extensions of individual staff members will be the same as in London.

10th anniversary of Andalusian Advanced Therapies Initiative
Asphalion opens new office in Amsterdam

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

ACEPTAR
Aviso de cookies